MacroGenics to Participate in Upcoming Investor Conferences

ROCKVILLE, MD, Nov. 03, 2021 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following conferences in November and December 2021:

• Credit Suisse 30^th Annual Healthcare Conference.  MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on Tuesday, November 9, 2021 at 8:00 am ET.
• Stifel 2021 Virtual Healthcare Conference.  MacroGenics’ management is scheduled to participate in a fireside chat on Tuesday, November 16, 2021 at 8:00 am ET, and will also participate in one-on-one meetings.
• Evercore ISI 4^th Annual HealthCONx Virtual Conference.  MacroGenics’ management is scheduled to participate in a fireside chat on Thursday, December 2, 2021 at 8:25 am ET, and will also participate in one-on-one meetings.
• JMP Securities Hematology and Oncology Summit.  MacroGenics’ management is scheduled to participate in a fireside chat on Monday, December 6, 2021 at 1:00 pm ET, and will also participate in one-on-one meetings.

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

About MacroGenics, Inc.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

CONTACTS:
Chris James, M.D., Vice President, Investor Relations & Corporate Communications
Jim Karrels, Senior Vice President, CFO
1-301-251-5172,  info@macrogenics.com